Mycroft-West, Courtney J, Devlin, Anthony J, Cooper, Lynsay C, Guimond, Scott E, Procter, Patricia, Guerrini, Marco, Miller, Gavin J, Fernig, David G 
ORCID: 0000-0003-4875-4293, Yates, Edwin A ORCID: 0000-0001-9365-5433, Lima, Marcelo A et al (show 1 more authors)
(2021)
Glycosaminoglycans from <i>Litopenaeus vannamei</i> Inhibit the Alzheimer's Disease β Secretase, BACE1.
MARINE DRUGS, 19 (4).
203-.
Abstract
Only palliative therapeutic options exist for the treatment of Alzheimer's Disease; no new successful drug candidates have been developed in over 15 years. The widely used clinical anticoagulant heparin has been reported to exert beneficial effects through multiple pathophysiological pathways involved in the aetiology of Alzheimer's Disease, for example, amyloid peptide production and clearance, tau phosphorylation, inflammation and oxidative stress. Despite the therapeutic potential of heparin as a multi-target drug for Alzheimer's disease, the repurposing of pharmaceutical heparin is proscribed owing to the potent anticoagulant activity of this drug. Here, a heterogenous non-anticoagulant glycosaminoglycan extract, obtained from the shrimp <i>Litopenaeus vannamei,</i> was found to inhibit the key neuronal β-secretase, BACE1, displaying a more favorable therapeutic ratio compared to pharmaceutical heparin when anticoagulant activity is considered.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | Alzheimer’, s disease, amyloid-β, BACE1, β, -secretase, glycosaminoglycan, chondroitin sulfate, heparin, heparan sulphate, Litopenaeus vannamei |
| Divisions: | Faculty of Health and Life Sciences Faculty of Health and Life Sciences > Institute of Systems, Molecular and Integrative Biology |
| Depositing User: | Symplectic Admin |
| Date Deposited: | 07 Jul 2021 10:06 |
| Last Modified: | 09 Feb 2024 04:31 |
| DOI: | 10.3390/md19040203 |
| Open Access URL: | https://doi.org/10.3390/md19040203 |
| Related URLs: | |
| URI: | https://livrepository.liverpool.ac.uk/id/eprint/3129115 |
Dimensions
Dimensions
